

Rademikibart

Cat. No.:	HY-P990090
CAS No.:	2648260-80-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4R α with a KD of 20.7 pM when binding to human IL-4R α epitopes. Rademikibart does not bind to IL-4R α from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research^[1].

REFERENCES

[1]. Limin Zhang, et al. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R α , for the treatment of Th2 inflammatory diseases. *Sci Rep.* 2023 Jul 31;13(1):12411.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA